Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 6.25B -5.7% |
| Revenue (ttm) | 239.92M +53.5% |
| Net Income | -210.22M |
| EPS | -3.12 |
| Shares Out | 68.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,411,378 |
| Open | 89.67 |
| Previous Close | 89.64 |
| Day's Range | 89.41 - 93.35 |
| 52-Week Range | 74.50 - 122.20 |
| Beta | 2.01 |
| Analysts | Buy |
| Price Target | 138.88 (+52.99%) |
| Est. Earnings | Nov 3, 2026 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic... [Read more]
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for RYTM stock is "Buy." The 12-month stock price target is $138.88, which is an increase of 52.99% from the latest price.
News
Rhythm Pharmaceuticals price target raised to $150 from $149 at BofA
BofA raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $150 from $149 and keeps a Buy rating on the shares. The firm rolled the quarter and made “slight…
Rhythm Pharmaceuticals price target raised to $159 from $155 at RBC Capital
RBC Capital analyst Lisa Walter raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $159 from $155 and keeps an Outperform rating on the shares as part of a…
Rhythm announces Health Canada has approved IMCIVREE
Rhythm Pharmaceuticals (RYTM) announced that Health Canada has approved IMCIVREE for the additional indication of weight management in adult and pediatric patients 4 years of age and older with acquir...
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra...
Rhythm Pharmaceuticals initiated with an Outperform at Wolfe Research
Wolfe Research analyst Kalpit Patel initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating.
Rhythm Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing three strategic pillars—genetic obesity, HO, and Prader-Willi—with IMCIVREE and next-gen MC4R agonists. Early HO launch shows broad physician interest, with payer adoption strong and international expansion underway. Key clinical and regulatory milestones are expected by year-end.
Rhythm Pharmaceuticals assumed with an Outperform at Leerink
Leerink assumed coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating and $133 price target Rhythm is emerging as a leader in rare obesity through its differentiated MC4R franchise, with...
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated...
Rhythm Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
The business is advancing three rare disease pillars, with a strong HO launch showing broad prescriber engagement and favorable payer trends. Prader-Willi development is progressing with positive phase II data and strategic plans for pivotal trials. Financially, the company is well-resourced to invest in growth and R&D.
Rhythm Pharmaceuticals Slides: Corporate presentation
Rhythm Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank
Deutsche Bank analyst David Hoang initiated coverage of Rhythm Pharmaceuticals (RYTM) with a Hold rating and $120 price target Rhythm is a leader in rare neuroendocrine diseases with its MC4R…
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference
IMCIVREE continues to expand globally, with strong AHO launch momentum and broad physician adoption. Pipeline advances include upcoming phase III trials for oral and injectable MC4R agonists and plans for a pivotal PWS study. Cash reserves support operations for two years.
Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital
RBC Capital raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $155 from $141 and keeps an Outperform rating on the shares.
Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $154 from $151 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $142 and keeps a Buy rating on the shares.
Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
Citizens raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $160 from $155 and keeps an Outperform rating on the shares. Imcivree sales beat expectations, with strong HO launch…
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals said on Tuesday its experimental weekly injectable drug helped reduce body weight in patients with a rare form of obesity caused by damage to the brain, according to prelimina...
Rhythm Pharmaceuticals Earnings Call Transcript: Q2 2026
IMCIVREE's U.S. launch for acquired hypothalamic obesity drove strong Q2 sales growth, with robust early demand, broad prescriber engagement, and positive payer response. International expansion and next-generation MC4R agonist development are progressing, supporting long-term growth.
Rhythm Pharmaceuticals Earnings release: Q2 2026
Rhythm Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Rhythm Pharmaceuticals Slides: Q2 2026
Rhythm Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Rhythm Pharmaceuticals Quarterly report: Q2 2026
Rhythm Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial
Rhythm Pharmaceuticals (RYTM) announced preliminary results from the ongoing Phase 2 trial evaluating RM-718, Rhythm’s investigational once-weekly MC4R agonist, in patients with acquired hypothalamic ...